Related Experiment Video
Updated: Oct 14, 2025
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root
Yingjuan J Lu1, Leroy W Wheeler1, Haiyan Chu1
1Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
Abstract:
Provoked by sterile/nonsterile insults, prolonged monocyte mobilization and uncontrolled monocyte/macrophage activation can pose imminent or impending harm to the affected organs. Curiously, folate receptor beta (FRβ), with subnanomolar affinity for the vitamin folic acid (FA), is upregulated during immune activation in hematopoietic cells of the myeloid lineage. This phenomenon has inspired a strong interest in exploring FRβ-directed diagnostics/therapeutics. Previously, we have reported that FA-targeted aminopterin (AMT) therapy can modulate macrophage function and effectively treat animal models of inflammation. Our current investigation of a lead compound (EC2319) leads to discovery of a highly FR-specific mechanism of action independent of the root causes against inflammatory monocytes. We further show that EC2319 suppresses interleukin-6/interleukin-1β release by FRβ+ monocytes in a triple co-culture leukemic model of cytokine release syndrome with anti-CD19 chimeric antigen receptor T cells. Because of its chemical stability and metabolically activated linker, EC2319 demonstrates favorable pharmacokinetic characteristics and cross-species translatability to support future pre-clinical and clinical development.
Insights
A new compound, EC2319, targets folate receptor beta (FRβ)-expressing monocytes to reduce harmful inflammation. This FRβ-specific therapy shows promise for treating inflammatory conditions and cytokine release syndrome.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Uncontrolled monocyte/macrophage activation causes organ damage during inflammation.
- Folate receptor beta (FRβ) is upregulated on activated myeloid cells.
- FRβ-targeted therapies are of significant interest for treating inflammatory diseases.
Purpose of the Study:
- To investigate a novel FRβ-specific compound, EC2319, for treating inflammatory monocytes.
- To elucidate the mechanism of action of EC2319.
- To evaluate EC2319's efficacy in a model of cytokine release syndrome.
Main Methods:
- Investigated EC2319's FRβ-specific mechanism of action.
- Utilized a triple co-culture leukemic model involving anti-CD19 chimeric antigen receptor T cells.
- Assessed interleukin-6 and interleukin-1β release from FRβ+ monocytes.
Main Results:
- EC2319 exhibits a highly FRβ-specific mechanism of action against inflammatory monocytes, independent of insult type.
- EC2319 effectively suppresses interleukin-6/interleukin-1β release in a cytokine release syndrome model.
- EC2319 demonstrates favorable pharmacokinetics and cross-species translatability.
Conclusions:
- EC2319 represents a promising FRβ-targeted therapeutic strategy for inflammatory conditions.
- The compound's specificity and favorable characteristics support further pre-clinical and clinical development.
- FRβ-directed therapy offers a novel approach to modulate monocyte/macrophage activation in disease.
More Related Videos
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
11:48Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Related Concept Videos
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:38Inflammation